Sam Samad joined Illumina in 2017 and holds the role of Senior Vice President and Chief Financial Officer with responsibility for the company’s finance, accounting, investor relations, internal audit, and treasury functions. Sam was previously at Cardinal Health, and served as Senior Vice President and Chief Financial Officer for the Pharmaceutical Segment. Sam was appointed as Corporate Treasurer for Cardinal Health in February of 2012. He currently has responsibility for treasury, credit and collections and tax in addition to his direct responsibility for the finance organization of Cardinal Health’s China business. Prior to Cardinal Health, Sam was with Eli Lilly and Company where he spent 12 years in various international leadership roles in finance and in the business. His last position with Lilly prior to joining Cardinal Health was as Chief Financial Officer of Eli Lilly Canada. In addition to Sam’s responsibilities at Cardinal Health, he was treasurer and a board member for the Cardinal Health Foundation.
Across both studies, serum HI antibody responses to Flulaval met the pre-specified seroconversion criteria for all 3 virus strains, and also the pre-specified criterion for the proportion of subjects with HI titers ≥1:40 for both influenza A viruses. In both trials, both Flulaval and the comparator vaccine did not meet the pre-specified criterion for the proportion of subjects with HI titers ≥1:40 for the influenza B virus. The clinical relevance of this finding on vaccine-induced protection against illness caused by influenza type B strains is unknown.